Business Description
Esperion Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29664W1053
Share Class Description:
ESPR: Ordinary SharesTotal Employee Number:
294Compare
Compare
Traded in other countries / regions
ESPR.USA0ET.Germany0IIM.UK Index Membership
Russell 2000Russell 3000Russell 3000Russell 2000 IPO Date
2013-06-26Description
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.62 | |||||
Equity-to-Asset | -0.67 | |||||
Debt-to-Equity | -0.82 | |||||
Debt-to-EBITDA | 3.18 | |||||
Interest Coverage | 0.89 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.47 | |||||
Beneish M-Score | -1.91 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.5 | |||||
3-Year EPS without NRI Growth Rate | 68.5 | |||||
3-Year FCF Growth Rate | 71.2 | |||||
3-Year Book Growth Rate | 34.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.56 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.7 | |||||
9-Day RSI | 59.51 | |||||
14-Day RSI | 64.22 | |||||
3-1 Month Momentum % | 20.31 | |||||
6-1 Month Momentum % | -15.36 | |||||
12-1 Month Momentum % | 173.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.53 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 0.52 | |||||
Days Inventory | 293.45 | |||||
Days Sales Outstanding | 101.33 | |||||
Days Payable | 197.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -48.7 | |||||
Shareholder Yield % | 0.6 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.38 | |||||
Operating Margin % | 18.12 | |||||
Net Margin % | -1.78 | |||||
EBITDA Margin % | 19.01 | |||||
FCF Margin % | -4.39 | |||||
OCF Margin % | -4.35 | |||||
ROA % | -1.89 | |||||
ROIC % | 49.57 | |||||
3-Year ROIIC % | 191.47 | |||||
ROC (Joel Greenblatt) % | 1010.4 | |||||
ROCE % | 91.55 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 68.6 | |||||
PS Ratio | 1.68 | |||||
EV-to-EBIT | 11.47 | |||||
EV-to-Forward-EBIT | 11.66 | |||||
EV-to-EBITDA | 11.46 | |||||
EV-to-Forward-EBITDA | 11.66 | |||||
EV-to-Revenue | 2.18 | |||||
EV-to-Forward-Revenue | 2.02 | |||||
EV-to-FCF | -49.56 | |||||
Price-to-GF-Value | 1.34 | |||||
Earnings Yield (Greenblatt) % | 8.72 | |||||
FCF Yield % | -2.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ESPR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Esperion Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 418.244 | ||
| EPS (TTM) ($) | -0.1 | ||
| Beta | 3.5503 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 1.49 | ||
| Volatility % | 99.51 | ||
| 14-Day RSI | 64.22 | ||
| 14-Day ATR ($) | 0.02632 | ||
| 20-Day SMA ($) | 3.152 | ||
| 12-1 Month Momentum % | 173.04 | ||
| 52-Week Range ($) | 1.1 - 4.175 | ||
| Shares Outstanding (Mil) | 257.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Esperion Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Esperion Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 127 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 126 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 33 days | ||
| General meeting for 2026 | 2026-05-28 08:00 | 3.13 (+0.16%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 3.15 (+1.12%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.15 (+1.12%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 09:30 | 2.17 (-0.91%) | ||
| The Citizens Life Sciences Conference | 2026-03-11 08:25 | 2.70 (-13.46%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-10 08:00 | 3.04 (+13.86%) |
Show
Entries
Esperion Therapeutics Inc Frequently Asked Questions
What is Esperion Therapeutics Inc(ESPR)'s stock price today?
The current price of ESPR is $3.16. The 52 week high of ESPR is $4.18 and 52 week low is $1.10.
When is next earnings date of Esperion Therapeutics Inc(ESPR)?
The next earnings date of Esperion Therapeutics Inc(ESPR) is 2026-08-05 Est..
Does Esperion Therapeutics Inc(ESPR) pay dividends? If so, how much?
Esperion Therapeutics Inc(ESPR) does not pay dividend.
Guru Commentaries on NAS:ESPR
No articles.
Press Release
Articles on Esperion Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers